Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. - Wikidata - wikimedia - TriplyDB

Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia.

Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q33344749

about

Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia Monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment An update on the management of chronic lymphocytic leukaemia.Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies.Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia.Alemtuzumab for B-cell chronic lymphocytic leukemia.Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes.Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia.A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia.The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.The spectrum of use of rituximab in chronic lymphocytic leukemia Role of rituximab in first-line treatment of chronic lymphocytic leukemia.Antibody therapy for chronic lymphocytic leukemia.Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives.Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712 Choosing first-line therapy for chronic lymphocytic leukemia.Cladribine and Fludarabine Nucleoside Change the Levels of CD Antigens on B-Lymphoproliferative Disorders.Clinical use of rituximab in haematological malignancies.Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model.Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL).Immunoglobulin mutational status detected through single-round amplification of partial V(H) region represents a good prognostic marker for clinical outcome in chronic lymphocytic leukemia.Role of CD20 monoclonal antibodies in previously untreated chronic lymphocytic leukemia.Monoclonal antibody therapy of leukaemias and lymphomas.Recent advances in chronic lymphocytic leukemia.Fludarabine in chronic lymphocytic leukaemia.Evolving role of monoclonal antibodies in the treatment of chronic lymphocytic leukemia.Hapten-enhanced overall survival time in advanced hepatocellular carcinoma by ultro-minimum incision personalized intratumoral chemoimmunotherapy.Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppression.Protective cancer immunotherapy: what can the innate immune system contribute?A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia.Changing paradigms in the treatment of chronic lymphocytic leukemia.Chronic lymphocytic leukemia: putting new treatment options into perspective.New angles of attack in the fight against chronic lymphocytic leukemia: the advent of novel non-chemotherapeutic agents.Expanded use of rituximab in the management of non-Hodgkin lymphoma.Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma.Detection methods of ZAP-70 in chronic lymphocytic leukemia.

P2860

Q24203027-B900C395-DEA8-4A0C-9CA2-B1A2BEF1592B Q24241519-81FC588F-E354-4FA4-85D5-8C61CE2CD9E5 Q28082086-43AE497A-E2AC-49F4-9F6C-511954A0CCB5 Q30341946-E8FC419C-F312-477C-B4F8-B8AB18ACA293 Q33361984-FA456AE3-E81C-49AA-ADCF-A2AD38392DA5 Q33375915-5FBA1DB0-0FDC-4360-82DE-3702CAD3B5AA Q33380135-9863A89D-E1CC-4CAE-ACCC-AC33A42E2B7B Q33382030-8FCACB97-E2AA-4B3C-98FE-CFD4999874EB Q33414468-DE21FC55-E0BB-4292-AF5F-3DA33E40BCC9 Q33573355-5794628B-6456-4E3C-BF79-C8C7AA4F471A Q33880538-7FB047CD-CFB9-4787-AFDE-266EFF691F30 Q34310845-0BB716EC-A457-492B-907F-14B69737DC34 Q34510030-99CC1499-7690-494C-AB5F-ED78FC392606 Q34574147-0EEC3264-5DE4-4C84-B792-ABF77FBEA253 Q34589909-138B8169-5A20-4F5E-8244-E45363BCA063 Q34700655-CCF2188A-2579-492D-B7F7-9EE9AAA05F2A Q34879367-22367525-8817-4D26-A038-50CFD764F4D7 Q35124844-736B3F56-EC36-4142-9E80-FC33FEC849FC Q35430828-3F9B41A4-FBED-427F-9AE2-509A3D5D33AD Q35561014-11EEECC0-4802-4836-ACAA-C9A873C40314 Q35626914-6003A0F3-EB61-4919-9B82-1E7EDD249C00 Q35683808-D9F5B492-9E80-43F9-858A-528EE358A041 Q35790006-5BB74174-22F8-4CBB-9C46-3F3B60298F45 Q36218799-F1BBD969-5900-4581-ACD6-6F131C0FD95A Q36239669-819E7531-D072-40CE-99BE-70F5229218AE Q36523498-39D87F5C-60F9-44DE-BFF3-EC45F3AC425F Q36548735-241F9791-C0AD-42A4-8AF1-EE5DACF4090B Q36985872-E2CEF473-BD35-411C-BF30-ED4AE795F54B Q37031758-E5DBE8FE-F8A8-49DD-8919-49DA5214ADF0 Q37032625-FC54FB9C-96A1-4AD0-BE67-1F54F03BC3FA Q37032632-8F21EF56-DDA8-4290-B3F5-DD53C08C28D8 Q37364653-5FC2DA7B-CE66-4D60-A5D9-20821D293E3C Q37418477-21228FAC-5146-4A2C-8B90-E6D8A3E9D7F0 Q37662198-3A543475-1598-4C9A-98C5-F1429F1C3543 Q37734199-BAB63D24-336D-4E5A-93F3-1F35AA27F98B Q37767703-D9E6BB04-EEBC-4384-85E0-CAA554FEEFA9 Q37771248-7C2D8891-A857-4212-B4FC-68BCC2164D00 Q37799820-2695D660-DE63-4E0A-8C6C-0DE4A1B570E4 Q37854714-46EBC115-A33E-42BA-9722-C4E7AA33910B Q37892409-95E5F064-A1D9-44D4-A359-3683D2858472

P2860

Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q33344749

description

2002 nî lūn-bûn

@nan

2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Phase 2 study of a combined im ...... chronic lymphocytic leukemia.

@ast

Phase 2 study of a combined im ...... chronic lymphocytic leukemia.

@en

type

label

Phase 2 study of a combined im ...... chronic lymphocytic leukemia.

@ast

Phase 2 study of a combined im ...... chronic lymphocytic leukemia.

@en

prefLabel

Phase 2 study of a combined im ...... chronic lymphocytic leukemia.

@ast

Phase 2 study of a combined im ...... chronic lymphocytic leukemia.

@en

P1433

Q33344749-968DE8F0-7F71-47A2-8527-14CB19F09D60

P1476

Q33344749-6F923A08-7B71-4BED-981C-B62BAB744E95

P2093

Q33344749-17B24A97-2AE6-4894-AB05-0C4596D21995

Q33344749-383D1999-22C0-4EC3-8168-969E75F5FF18

Q33344749-623D1D4E-253C-48D0-81CC-9A99751B5D7B

Q33344749-818E72EF-97BE-4DD9-BE7A-C68487CA7086

Q33344749-83097530-1BCA-468C-BF74-BC0BB8454559

Q33344749-94B1BA7D-2C10-4DDC-BA30-D65837D21700

Q33344749-A158604E-D805-4700-AA24-FBEF0A5FCBAD

Q33344749-A7B1618F-5A70-45B2-AC27-7D8CCD50FC26

Q33344749-AB31E2E1-97B2-4535-80A8-AF3052B28753

Q33344749-C1286A40-BF03-4D07-A306-0D0A75EACF18

P304

Q33344749-80E6C4D5-6D09-4DC1-816F-7D6F3DBB0D56

P31

Q33344749-D8B90D01-B795-49A0-B971-BDD24FE84A21

P356

Q33344749-51F1CFEB-6406-4430-9746-29A75DE9AE5F

P407

Q33344749-91AAE2B7-8426-4FF7-899B-EF717DA86154

P433

Q33344749-C34A83C2-0B11-4F43-A217-F54D3BD8B392

P478

Q33344749-9B4D3C7C-E6AA-446A-853E-96F208C6435A

P50

Q33344749-BC2E13B3-0BEF-48F1-949B-B82E28BDB03D

Q33344749-EADAFDFE-5082-4C93-BC25-95A3B670B342

P577

Q33344749-931B77FE-C734-4962-8BBB-BDA389595044

P5875

Q33344749-17C16D1D-C161-4AC1-9A53-F1E8AC151005

P698

Q33344749-512EF5E2-D6D6-4601-94F8-D2AF2A261509

P921

Q33344749-0A0A3C7D-0BDA-410C-8CBA-01A6EC4860A2

Q33344749-4193BB25-D388-4895-B20A-0863838DD650

P356

BLOOD-2002-03-0972

P1433

P1476

Phase 2 study of a combined im ...... chronic lymphocytic leukemia.

@en

P2093

Andreas Engert

http://www.w3.org/2001/XMLSchema#string

Axel Hinke

http://www.w3.org/2001/XMLSchema#string

Dieter Huhn

http://www.w3.org/2001/XMLSchema#string

German CLL Study Group

http://www.w3.org/2001/XMLSchema#string

Holger Schulz

http://www.w3.org/2001/XMLSchema#string

Manfred Hensel

http://www.w3.org/2001/XMLSchema#string

Marcel Reiser

http://www.w3.org/2001/XMLSchema#string

Michael Herold

http://www.w3.org/2001/XMLSchema#string

Saskia Karina Klein

http://www.w3.org/2001/XMLSchema#string

Ute Rehwald

http://www.w3.org/2001/XMLSchema#string

P304

3115-3120

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2002-03-0972

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P50

German CLL Study Group

P577

2002-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11077369

http://www.w3.org/2001/XMLSchema#string

P698

12384407

http://www.w3.org/2001/XMLSchema#string

P921